ChemoMetec A/S (CPH:CHEMM)

Market Cap	10.61B +19.0%
Revenue (ttm)	495.57M +21.5%
Net Income	186.41M +36.8%
EPS	10.71 +36.8%
Shares Out	17.40M
PE Ratio	56.91
Forward PE	41.40
Dividend	7.00 (1.15%)
Ex-Dividend Date	Oct 10, 2025

Volume	31,603
Average Volume	30,273
Open	608.50
Previous Close	610.50
Day's Range	608.00 - 617.00
52-Week Range	367.00 - 804.00
Beta	1.47
RSI	28.75
Earnings Date	Feb 4, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 170
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: CHEMM

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.